Investigations on gossypol: Past and present developments

Expert Opinion on Investigational Drugs

Volumn 14, Issue 11, 2005, Pages 1419-1434

  Dodou, Kalliopi ^a  

^a UNIVERSITY OF SUNDERLAND   (United Kingdom)

Author keywords

Anti inflammatory; Antiapoptotic; Antimalarial; Antioxidant; Antiproliferative; Antitumour; Bcl xL; BH3 mimetic; Enzyme inhibition; Gossypol; Gossypol derivatives; HIV 1; Natural product; Psoriasis

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ADENYLATE CYCLASE; ALDEHYDE REDUCTASE; CALCINEURIN; CATECHOL METHYLTRANSFERASE; CELL CYCLE PROTEIN; CHLOROQUINE; CISPLATIN; CYTOCHROME P450; DACARBAZINE; DNA DIRECTED DNA POLYMERASE ALPHA; DNA DIRECTED DNA POLYMERASE BETA; FERROUS ASCORBATE; GLUTATHIONE TRANSFERASE; GOSSYPOL; GOSSYPOL DERIVATIVE; LACTATE DEHYDROGENASE; LIPID; MALE CONTRACEPTIVE AGENT; MELPHALAN; PHOSPHOLIPASE A2; PLASMID DNA; PROTEIN KINASE C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REGULATOR PROTEIN; SCHIFF BASE; STEROID 5ALPHA REDUCTASE; THIOBARBITURIC ACID; UNINDEXED DRUG; ZIDOVUDINE;

ABDOMINAL DISEASE; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; BIOLOGICAL ACTIVITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CELL MEMBRANE; CELL PROLIFERATION; CLINICAL TRIAL; COTTON; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; DRUG TOLERABILITY; GLIOBLASTOMA; HUMAN; HYPOGLYCEMIA; HYPOKALEMIA; IC 50; ILEUS; KERATINOCYTE; LIVER TOXICITY; MITOCHONDRIAL MEMBRANE; NEPHROTOXICITY; NONHUMAN; REVIEW; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ANTIVIRAL AGENTS; CELL MEMBRANE; GOSSYPOL; HUMANS; MITOCHONDRIAL MEMBRANES;

EID: 27744431949     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.11.1419     Document Type: Review

References (109)

1. KING TJ, DE SILVA LB: Optically active gossypol from Thespesia Populnea. Tet. Lett. (1968) 3:261-263.
2. JAROSZEWSKI JW, STROM-HANSEN T, HANSEN SH, THASTRUP O, KOFOD H: On the botanical distribution of chiral forms of gossypol. Planta Med. (1992) 58:454-458.
3. STIPANOVIC R, STOESSL A, STOTHERS JB, ALTMAN DW, BELL AA, HEINSTEIN P: The stereochemistry of the biosynthetic precursor of gossypol. J. Chem. Soc. Chem. Commun. (1986):100-102.
4. ABOU-DONIA MB: Physiological effects and metabolism of gossypol. Residue Rev. (1976) 61:125-160.
5. ADAMS R, MORRIS RC, GEISSMAN TA, BUTTERBAUGH DJ, KIRKPATRICK EC: Structure of gossypol. An interpretation of its reaction. J. Am. Chem. Soc. (1938) 60:2193-2203.
6. EDWARDS JD: Total synthesis of gossypol. J. Am. Chem. Soc. (1958) 80:3798-3799.
7. WU D: An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive and in gynaecological disease. Drugs (1989) 38(3):333-341.
8. COUTINHO EM: Gossypol: a contraceptive for men. Contraception (2002) 65:259-263.
9. FREEDMAN TB, CAO X, OLIVIERA RV, CASS QB, NAFIE L: Determination of the absolute configuration and solution conformation of gossypol by vibrational circular dichroism. Chirality (2003) 15:196-200.
10. JAROSZEWSKI JW, STROM-HANSEN T, HANSEN LL: Optical stability of gossypol. Chirality (1992) 4:216-221.
11. 1H NMR studies of gossypol and its complexes with some organic compounds. J. Mol. Struct. (1990) 220:261-268.
12. MARCINIAK B, SCHROEDER G, KOZUBEK H, BRZEZINSKI B: Spectroscopic and kinetic studies of the aldehyde-lactol tautomerisation of gossypol in solution. J. Chem. Soc. Perkin Trans. (1991) 2:1359-1362.
13. 3+ cations. J. Mol. Struct. (2001) 569:147-155.
14. 31P nuclear magnetic resonance and toxicity studies. Cancer Res. (1990) 50:6936-6943.
15. OLIVER CL, BAUER JA, WOLTER KG et al.: In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin. Cancer Res. (2004) 10(22):7757-7763.
16. BAUER JA, TRASK DK, KUMAR B et al.: Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-Xl. Mol. Cancer Ther. (2005) 4(7):1096-1104.
17. SHELLEY MD, HARTLEY L, GROUNDWATER PW et al.: Structure-activity studies on gossypol in tumour cell lines. Anticancer Drugs (2000) 11(3):209-216.
18. BLACKSTAFFE L, SHELLEY MD, FISH RG: Cytotoxicity of gossypol enantiomers and its quinone metabolite gossypolone in melanoma cell lines. Melanoma Res. (1997) 7:364-372.
19. STEIN RC, JOSEPH AEA, MATLIN SA et al.: A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother. Pharmacol. (1992) 30:480-482.
20. FLACK MR, PYLE RG, MULLEN NM et al.: Oral gossypol in the treatment of metastatic adrenal cancer. J. Clin. Endocrinol. Metab. (1993) 76(4):1019-1024.
21. BUSHUNOW P, REIDENBERG MM, WASENKO J et al.: Gossypol treatment of recurrent adult malignant gliomas. J. Neurooncol. (1999) 43:79-86.
22. VAN POZNAK C, SEDMAN AD, REIDENBERG MM et al.: Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a Phase I/II clinical trial. Breast Cancer Res. Treatment (2001) 66:239-248.
23. QIU J, LEVIN LR, BUCK J, REIDENBERG MM: Different pathways of cell killing by gossypol enantiomers. Exp. Biol. Med. (2002) 227(6):398-401.
24. RADLOFF RJ, DECK LM, ROYER RE, VANDER JAGT DL: Antiviral activities of gossypol and its derivatives against herpes simplex virus type II. Pharmacol. Res. Commun. (1986) 18(11):1063-1073.
25. LIN TS, SCHINAZI R, GRIFFITH BP et al.: Selective inhibition of human immunodeficiency virus type 1 by the (-) but not the (+) enantiomer of gossypol. Antimicrob. Agents Chemother. (1989) 3(12):2149-2151.
26. RAZAKANTOANINA V, PHUNG NKP, JAUREGUIBERRY G: Antimalarial activity of new gossypol derivatives. Parasit. Res. (2000) 86:665-668.
27. VANDER JAGT DL, DECK LM, ROYER RE: Gossypol: prototype of inhibitors targeted to dinucleotide folds. Cur. Med. Chem. (2000) 7:479-498.
28. GONZALEZ-GARZA MT, MATLIN SA, MATA-CARDENAS B, SAID-FERNANDEZ S: Differential effects of the (+) and (-)-gossypol enantiomers upon Entamoeba histolytica axenic cultures. J. Pharm. Pharmacol. (1993) 45:144-145.
29. MONTAMAT EE, BURGOS C, GEREZ DE BURGOS NM, ROVAI LE, BLANCO A, SEGURA EL: Inhibitory action of gossypol on enzymes and growth of Trypanosoma cruzi. Science (1982) 218:288-289.
30. DODOU K, ANDERSON RJ, LOUGH WJ, SMALL DAP, SHELLEY MD, GROUNDWATER PW: Synthesis of gossypol atropisomers and derivatives and evaluation of their antiproliferative and antioxidant activity. Bioorg. Med. Chem. (2005) 13(13):4228-4237.
31. JANERO DR, BURGHARDT B: Protection of rat myocardial phospholipid against peroxidative injury through superoxide- (xanthine oxidase)-dependent, iron-promoted Fenton chemistry by the male contraceptive gossypol. Biochem. Pharmacol. (1988) 37(17):3335-3342.
32. LAUGHTON MJ, HALLIWELL B, EVANS PJ, HOULT JR: Antioxidant and prooxidant actions of the phenolics quercetin, gossypol, and myricetin. Biochem. Pharmacol. (1989) 38(17):2859-2865.
33. LI ASH, BANDY B, TSANG SS, DAVISON AJ: DNA-breaking versus DNA-protecting activity of four phenolic compounds in vitro. Free Rad. Res. (2000) 33:551-566.
34. JOSEPH AEA, MATLIN SA, KNOX P: Cytotocity of enantiomers of gossypol. Br. J. Cancer (1986) 54:511-513.
35. LEE CYG, MOON YS, YUAN JH, CHEN AF: Enzyme inactivation and inhibition by gossypol. Mol. Cel. Biochem. (1982) 47:65-70.
36. UENO H, SAHNI MK, SEGAL SJ, KOIDE SS: Interaction of gossypol with sperm macromolecules and enzymes. Contraception (1988) 37(3):333-341.
37. BURGOS C, GEREZ DE BURGOS NM, ROVAI LE, BLANCO A: In vitro inhibition by gossypol of oxidoreductases from human tissues. Biochem. Pharmacol. (1986) 35(5):801-804.
38. CONNERS R, SCHAMBACH F, READ J et al.: Mapping the binding site of gossypol-like inhibitors of Plasmodium falciparum lactate dehydrogenase. Mol. Biochem. Parasitol. (2005) 142:137-148.
39. 4. Biochem. Pharmacol. (2001) 62:81-89.
40. McCLARTY GA, CHAN AK, CREASY DC, WRIGHT JA: Ribonucleotide reductase: an intracellular target for the male antifertility agent, gossypol. Biochem. Biophys. Res. Commun. (1985) 133(1):300-305.
41. VAINIO P, THUREN T, WICHMAN K, LUUKKAINEN T, KINNUNEN PK: Hydrolysis of phospholipids monolayers by human spermatozoa. Inhibition by male contraceptive gossypol. Biochim. Biophys. Acta (1985) 814(2):405-408.
42. TENG CS: Gossypol-induced apoptotic DNA fragmentation correlates with inhibited protein kinase C activity. Contraception (1995) 52:389-395.
43. TUSZYNSKI GP, COSSU G: Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines. Cancer Res. (1984) 44:768-771.
44. COYLE T, LEVANTE S, SHETLER M, WINFIELD J: In vitro and in vivo cytotoxicity of gossypol against central nervous system tumour cell lines. J. Neuroonc. (1994) 19:25-35.
45. WANG YC, RAO PN: Effect of gossypol on DNA synthesis and cell cycle progression of mammalian cells in vitro. Cancer Res. (1984) 44:35-38.
46. TANG F, TSANG AYF, LEE C, WONG PYD: Inhibition of catechol-O-methyl transferase by gossypol: the effect of plasma proteins. Contraception (1982) 26(5):515-519.
47. SMIT NPM, PAVEL S, KAMMEYER A, WESTERHOF W: Determination of catechol-O-methyl transferase activity in relation to melanin metabolism using high performance liquid chromatography with fluorimetric detection 1. Anal. Biochem. (1990) 190:286-291.
48. REKHA GK, SLADEK NE: Inhibition of human class 3 aldehyde dehydrogenase, and sensitisation of tumour cells that express significant amounts of this enzyme to oxazaphosphorines, by the naturally occurring compound gossypol. In: Enzymology and Molecular Biology of Carbonyl Metabolism. Weiner H, Crabb DW, Flynn TG et al. (Eds), Plenum Press, New York, USA (1996) 6:133-146.
49. MESSIHA FS: Effect of gossypol on kinetics of mouse liver alcohol and aldehyde dehydrogenase. Gen. Pharmacol. (1991) 22(4):573-576.
50. BENZ CC, KENIRY MA, FORD JM et al.: Biochemical correlates of the antitumour and antimitochondrial properties of gossypol enantiomers. Mol. Pharmacol. (1990) 37:840-847.
51. FORD JM, HAIT WN, MATLIN SA, BENZ CC: Modulation of resistance to alkylating agents in cancer cell by gossypol enantiomers. Cancer Lett. (1991) 56:85-94.
52. JARVIS WD, TURNER AJ, POVIRK LF, TRAYLOR RS, GRANT S: Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukaemia cells by pharmacological inhibitors of protein kinase C. Cancer Res. (1994) 54(7):1707-1714.
53. ROSENBERG LJ, ADLAKHA RC, DESAI DM, RAO PN: Inhibition of DNA polymerase α by gossypol. Biochim. Biophys. Acta (1986) 866:258-267.
54. KABLE EP, PARSONS PG: Potency, selectivity and cell cycle dependence of catechols in human tumour cells in vitro. Biochem. Pharmacol. (1988) 37(9):1711-1715.
55. MEGO M: Telomerase inhibitors in anticancer therapy: gossypol as a potential telomerase inhibitor. Bratisl. Lek. Listy. (2002) 103(10):378-381.
56. HIIPAKKA RA, ZHANG HZ, DAI W, DAI Q, LIAO S: Structure-activity relationships for inhibition of human 5α-reductases by polyphenols. Biochem. Pharmacol. (2002) 63:1165-1176.
57. TRIPATHI AK, DESAI PV, PRADHAN A et al.: An α-proteobacterial type malate dehydrogenase may complement LDH function in Plasmodium falciparum. Eur. J. Biochem. (2004) 271:3488-3502.
58. DANDO C, SCHROEDER ER, HUNSAKER LA et al.: The kinetic properties and sensitivities to inhibitors of lactate dehydrogenases (LDH1 and LDH2) from Toxoplasma gondii: comparisons with pLDH from Plasmodium falciparum. Mol. Biochem. Parasitol. (2001) 118(1):23-32.
59. GEREZ DE BURGOS NM, BURGOS C, MONTAMAT EE, ROVAI LE, BLANCO A: Inhibition by gossypol of oxidoreductases from Trypanosoma cruzi. Biochem. Pharmacol. (1984) 33(7):955-959.
60. LIN TS, SCHINAZI RF, ZHU J et al.: Anti-HIV-1 activity and cellular pharmacology of various analogs of gossypol. Biochem. Pharmacol. (1993) 46(2):251-255.
61. KELLER PA, BIRCH C, LEACH SP, TYSSEN D, GRIFFITH R: Novel pharmacophore-based methods reveal gossypol as a reverse transcriptase inhibitor. J. Mol. Graphics Model. (2003) 21:365-373.
62. REIDENBERG MM: Environmental inhibition of 11β-hydroxysteroid dehydrogenase. Toxicology (2000) 144:107-111.
63. SONG D, LORENZO B, REIDENBERG MM: Inhibition of 11β-hydroxysteroid dehydrogenase by gossypol and bioflavonoids. J. Lab. Clin. Med. (1992) 120(5):792-797.
64. SANG GW, LORENZO B, REIDENBERG MM: Inhibitory effects of gossypol on corticosteroid 11-β-hydroxysteroid dehydrogenase from guinea pig kidney: a possible mechanism for causing hypokalaemia. J. Steroid Biochem. Molec. Biol. (1991) 39(2):169-176.
65. MOH PP, LI PK, DARBY MV, BRUEGGEMEIER RW, LIN YC: Characteristics of covalent gossypol binding to microsomal proteins. Res. Commun. Chem. Path. Pharmacol. (1992) 76(3):305-322.
66. YU YW: Probing into the mechanism of action, metabolism and toxicity of gossypol by studying its (+) and (-) stereoisomers. J. Ethnopharmacol. (1987) 20:65-78.
67. DECK LM, CHAMBLEE BB, ROYER RE, HUNSAKER LA, VANDER JAGT DL: Inhibition of aldose reductase by gossypol and gossypol-related compounds. In: Enzymology and molecular biology of carbonyl metabolism. Weiner H (Ed.), Kluwer Academic/Plenum Publishers, New York, USA (1999) 7:487-491.
68. KAWANISHI K, UEDA H, MORIYASU M: Aldose reductase inhibitors from the nature. Curr. Med. Chem. (2003) 10(15):1353-1374.
69. 2: a probe for the kinetic effects of sulfate glycoconjugates. Biochemistry (1997) 36:12400-12411.
70. 2+ entry in intact cells. Biochim Biophys. Acta (2000) 1496:270-276.
71. 2 in normal human epidermis and in lesion-free epidermis of patients with psoriasis or eczema. Br. J. Dermatol. (1985) 112:135-147.
72. BAUMGRASS R, WEIWAD M, ERDMANN F et al.: Reversible inhibition of calcineurin by the polyphenolic aldehyde gossypol. J. Biol. Chem. (2001) 276(51):47914-47921.
73. PHYLLIS JW, DIAZ FG, O'REGAN MH, PILITSIS JG: Effects of immunosuppressants, calcineurin inhibition, and blockade of endoplasmic reticulum calcium channels on free fatty acid efflux from the ischaemic/reperfused rat cerebral cortex. Brain Res. (2002) 957(1):12-24.
74. OLGIATI KL, TOSCANO DG, ATKINS WM, TOSCANO WA: Gossypol inhibition of adenylate cyclase. Arch. Biochem. Biophys. (1984) 231(2):411-415.
75. LIU S, KULP SK, SUGIMOTO Y et al.: The (-)-enantiomer of gossypol possesses higher anticancer potency than racemic gossypol in human breast cancer. Anti-Cancer Res. (2002) 22:33-38.
76. LIGUEROS M, JEOUNG D, TANG B, HOCHHAUSER D, REIDENBERG MM, SONENBERG M: Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected fibrosarcoma cells. Br. J. Cancer (1997) 76(1):21-28.
77. 1) signal transduction pathway. Anti-Cancer Res. (2004) 24(1):91-100.
78. ZHANG M, LIU H, GUO R et al.: Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem. Pharmacol. (2003) 66:93-103.
79. KITADA S, LEONE M, SARETH S, ZHAI D, REED JC, PELLECCHIA M: Discovery, characterisation, and structure-activity relationships studies of proapoptotic polyphenols targetting B-cell lymphocyte/leukaemia-2 proteins. J. Med. Chem. (2003) 46(20):4259-4264.
80. OLIVER CL, MIRANDA MB, SHANGARY, LAND S, WANG S, JOHNSON DE: (-)-Gossypol acts on the mitochondria to overcome Bcl-2 and Bcl-XL-mediated apoptosis resistance. Mol. Cancer Ther. (2005) 4(1):23-31
81. MOHAMMAD RM, WANG S, ABOUKAMEEL A et al.: Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol. Cancer Ther. (2005) 4(1):13-21.
82. XU L, YANG D, WANG S et al.: (-)-Gossypol enhances response to radiation therapy and results in tumour regression of human prostate cancer. Mol. Cancer Ther. (2005) 4(2):197-205.
83. HOU DX, UTO T, TONG X et al.: Involvement of reactive oxygen species-independent mitochondrial pathway in gossypol-induced apoptosis. Arch. Biochem. Biophys. (2004) 428:179-187.
84. CHANG JS, HSU YL, KUO PL, CHIANG LC, LIN CC: Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalised human alveolar lung cancer cell line. Clin. Exp. Pharmacol. Physiol. (2004) 31(10):716-722.
85. KOCAK M, BOZDOGAN O, ERKEK E, ATASOY P, BIROL A: Examination of Bcl-2, Bcl-X and bax protein expression in psoriasis. Int. J. Dermatol. (2003) 42(10):789-793.
86. TAKAHASHI H, MANABE A, ISHIDA-YAMAMOTO A, HASHIMOTO Y, IIZUKA H: Aberrant expression of apoptosis-related molecules in psoriatic epidermis. J. Dermat. Science (2002) 28:187-197.
87. FUKUYA Y, HIGAKI M, HIGAKI Y, KAWASHIMA M: Effect of vitamin D3 on the increased expression of Bcl-xL in psoriasis. Arch. Dermatol. Res. (2002) 293(12):620-625.
88. CUELLAR A, RAMIREZ J: Further studies on the mechanism of action of gossypol on mitochondrial membrane. Int. J. Biochem. (1993) 25(8):1149-1155.
89. DE PEYSTER A, HYSLOP PA, KUHN CE, SAUERHEBER RD: Membrane structural/functional perturbations induced by gossypol. Effects on membrane order, liposome permeability, and insulin-sensitive hexose transport. Biochem. Pharmacol. (1986) 35(19):2193-3300.
90. TANPHAICHITR N, NAMKING M, TUPPER S, HANSEN C, WONG PTT: Gossypol effects on the structure and dynamics of phospholipid bilayers: a FT-IR study. Chem. Phys. Lipids (1995) 75:119-125.
91. SHELLEY MD, HARTLEY L, FISH RG et al.: Stereospecific cytotoxic effects of gossypol enantiomers and gossypolone in tumour cell lines. Cancer Lett. (1999) 135:171-180.
92. GILBERT NE, O'REILLY JE, CHANG CJG, LIN YC, BRUEGGEMEIR RW: Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Life Sci. (1995) 57(1):61-67.
93. MENG X, RIORDAN NH, RIORDAN HD et al.: Cell membrane fatty acid composition differs between normal and malignant cell lines. P. R. Health Sci. J. (2004) 23(2):103-106.
94. ZHUANG L, KIM J, ADAM RM, SOLOMON KR, FREEMAN MR: Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J. Clin. Invest. (2005) 115(4):959-968.
95. HERVE JC, BASTIDE FP, CRONIER L et al.: Contraceptive gossypol blocks cell-to-cell communication in human and rat cells. Eur. J. Pharmacol. (1996) 313:243-255.
96. KUHN G, CERMAK R, MINCK K, VUJICIC Z, SCHARRER E: Gossypol induces chloride secretion in rat proximal colon. Eur. J. Pharmacol. (2002) 457:187-194.
97. HUTCHINSON RW, BARHOUMI R, MILES JM, BURGHARDT RC: Attenuation of gossypol cytotoxicity by cyclic AMP in rat liver cell line. Toxicol. Appl. Pharmacol. (1998) 151(2):311-318.
98. HU F, MAH K, TERAMURA DJ: Gossypol effects on cultured normal and malignant melanocytes. In vitro Cel. Dev. Biol. (1986) 22(10):583-588.
99. CUELLAR A, DIAZ-SANCHEZ V, RAMIREZ J: Cholesterol side-chain cleavage and 11 β-hydroxylation are inhibited by gossypol in adrenal cortex mitochondria. J. Steroid Biochem. Mol. Biol. (1990) 37(4):581-585.
100. ABOU-DONIA MB, DIECKERT JW: Gossypol: uncoupling of the respiratory chain and oxidative phosphorylation. Life Sci. (1974) 14:1955-1963.
101. REYES J, WYRICK SD, BORRIERO L, BENOS DJ: Membrane actions of male contraceptive gossypol tautomers. Biochim. Biophys. Acta (1986) 863:101-109.
102. HAAS RH, SHIRLEY DA: The oxidation of gossypol. Formation of gossypolone with ferric chloride. J. Org. Chem. (1965) 30:4111-4113.
103. DAO VT, DOWD MK, GASPARD C et al.: New thioderivatives of gossypol and gossypolone, as prodrugs of cytotoxic agents. Bioorg. Med. Chem. (2003) 11:2001-2006.
104. DAO VT, GASPARD C, MAYER M, WERNER GH, NGUYEN SN, MICHELOT RJ: Synthesis and cytotoxicity of gossypol related compounds. Eur. J. Med. Chem. (2000) 35:805-813.
105. MILLER RF, ADAMS R: Structure of gossypol. Anhydrogossypol and its derivatives. J. Am. Chem. Soc. (1937) 59:1736-1738.
106. BAND V, HOFFER AP, BAND H et al.: Antiproliferative effect of gossypol and its optical isomers on human reproductive cancer cell lines. Gynecol. Oncol. (1989) 32:273-277.
107. LEBLANC M, RUSSO J, KUDELKA A, SMITH JA: An in vitro study of inhibitory activity of gossypol, a cottonseed extract, in human carcinoma cell lines. Pharmacol. Res. (2002) 46(6):551-555.
108. IKEDA M: Inhibition kinetics of NAD-linked enzymes by gossypol acetic acid. Andrologia (1990) 22:409-416.
109. WONG RC, NAKAGAWA Y, PERLMANN GE: Studies on the nature of the inhibition by gossypol of the transformation of pepsinogen to pepsin. J. Biol. Chem. (1972) 247(5):1625-1631.